ACTO Unveils AI Agents to Reshape Life Sciences Field Teams

TORONTO and NEW YORK – March 18, 2026 – Life sciences technology firm ACTO today announced a significant expansion of its artificial intelligence capabilities with the launch of ACTO AI, a suite of 17 specialized AI workflow agents. The new platform is engineered to automate and streamline critical, time-consuming tasks for pharmaceutical, biotech, and medtech organizations, aiming to redefine field team excellence.

This launch introduces a powerful set of tools designed to enhance the efficiency and impact of commercial learning teams, field managers, sales professionals, and medical science liaisons (MSLs). By targeting what the company calls 'high-friction workflows,' the AI agents promise to accelerate everything from employee training and certification to content governance and strategic reporting, all while maintaining stringent regulatory compliance.

Supercharging Field Teams with Intelligent Automation

The core promise of ACTO AI is to alleviate the administrative burden that often bogs down highly skilled life sciences professionals. The 17 workflow agents are designed to handle tasks that were previously manual and laborious. For learning and development teams, this means instantly generating training courses, AI-driven roleplay scenarios, and quizzes. For field managers, it automates the drafting of coaching reports, ensuring timely feedback without administrative delays.

Other key capabilities include:

• Content Governance: The AI agents can automatically clean up file nomenclature, identify duplicate assets, and manage content expiry dates, a critical function in the highly regulated world of medical content.
• Information Retrieval: A natural-language search layer allows field reps to instantly find specific, approved information within the platform, even during a high-stakes meeting with a healthcare professional (HCP).
• Strategic Insight: The platform adds a conversational query layer to dashboards, allowing senior leaders to quickly extract data-driven insights without complex report-building.

This move is a direct response to industry needs, developed from extensive feedback from the platform's community of over 50,000 field professionals. "Through thousands of customer conversations and hundreds of executive business reviews, we identified the high-friction workflows that consume valuable time and slow momentum around product launches, new hire onboarding, and field execution," said Parth Khanna, CEO of ACTO, in the company's announcement. "We built ACTO AI workflow agents to eliminate that friction—helping our customers move beyond managing tasks to delivering real impact."

A Competitive Edge in a Crowded AI Landscape

ACTO's launch comes as the life sciences sector rapidly embraces AI, with major players like IQVIA and Veeva also investing heavily in intelligent platforms. The market is becoming a hotbed of innovation, with a clear trend toward agentic AI systems that can manage complex workflows. Industry reports suggest that organizations are seeing significant returns, with some achieving a 2X return on investment within a year of implementing AI initiatives.

Against this competitive backdrop, ACTO is differentiating itself with a purpose-built strategy focused on 'Field Excellence' and what it calls 'empathetic AI.' Rather than offering a general-purpose AI, ACTO's agents are deeply specialized for the unique operational and regulatory demands of pharma and medtech. The company emphasizes a 'human-in-the-loop' philosophy, aiming to 'agentify' up to 30% of administrative work to augment, not replace, human professionals. This approach is designed to free up teams to focus on uniquely human strengths: judgment, strategic thinking, and building personal connections with HCPs.

Navigating the Gauntlet of Regulation and Ethics

Perhaps the most critical aspect of ACTO's strategy is its proactive approach to regulatory compliance. The life sciences industry operates under intense scrutiny, and the integration of AI introduces complex challenges related to data integrity, privacy, and accountability. Generic AI solutions often struggle to meet these stringent requirements.

ACTO's platform is FDA 21 CFR Part 11 validated, a crucial standard ensuring that electronic records and signatures are trustworthy, secure, and equivalent to their paper counterparts. This validation requires robust audit trails, secure user authentication, and system validation—all critical for proving compliance to regulators. Furthermore, the company's SOC 2 Type II certification provides an additional layer of assurance regarding data security, confidentiality, and privacy.

By building its AI on this compliant foundation, ACTO directly addresses the industry's primary concerns about the 'black box' nature of AI. It provides a framework of trust that is essential for adoption in an environment where errors can have significant consequences. This built-in compliance helps organizations avoid the pitfalls of data exposure, algorithmic bias, and opaque data handling that can stall AI initiatives and create legal risks under regulations like HIPAA and GDPR.

Beyond Automation: Augmenting Human Expertise

While efficiency is a major driver, ACTO's vision extends beyond simple automation. The ultimate goal is to empower field professionals, making them more competent, confident, and credible. By offloading tedious tasks, the platform enables sales reps and MSLs to dedicate more time to preparing for strategic interactions and building stronger relationships.

One of the most compelling examples of this philosophy is the platform's AI-powered roleplay simulations. These tools allow field reps to practice challenging conversations with virtual HCPs in a safe, judgment-free environment. The AI can simulate different personalities, specialties, and objections, providing immediate feedback and helping reps master the clinical narrative for a new therapy. This is not about replacing human coaching but about providing a scalable tool for continuous practice and skill refinement.

As life sciences organizations face mounting pressure to accelerate product launches amid growing human capital gaps, this combination of intelligent automation and human augmentation presents a compelling value proposition. The launch of ACTO AI signals a clear move toward a future where technology handles the repetitive work, allowing skilled professionals to focus on the strategic and interpersonal elements that drive success.